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210 Original ResearchBACKGROUND: Bronchoscopy is often the initial diagnostic procedure performed in patients
with pulmonary lesions suggestive of lung cancer. A bronchial genomic classiﬁer was pre-
viously validated to identify patients at low risk for lung cancer after an inconclusive
bronchoscopy. In this study, we evaluated the potential of the classiﬁer to reduce invasive
procedure utilization in patients with suspected lung cancer.
METHODS: In two multicenter trials of patients undergoing bronchoscopy for suspected lung
cancer, the classiﬁer was measured in normal-appearing bronchial epithelial cells from a
mainstem bronchus. Among patients with low and intermediate pretest probability of cancer
(n ¼ 222), subsequent invasive procedures after an inconclusive bronchoscopy were iden-
tiﬁed. Estimates of the ability of the classiﬁer to reduce unnecessary procedures were
calculated.
RESULTS: Of the 222 patients, 188 (85%) had an inconclusive bronchoscopy and follow-up
procedure data available for analysis. Seventy-seven (41%) patients underwent an addi-
tional 99 invasive procedures, which included surgical lung biopsy in 40 (52%) patients.
Benign and malignant diseases were ultimately diagnosed in 62 (81%) and 15 (19%) patients,
respectively. Among those undergoing surgical biopsy, 20 (50%) were performed in patients
with benign disease. If the classiﬁer had been used to guide decision making, procedures
could have been avoided in 50% (21 of 42) of patients undergoing further invasive testing.
Further, among 35 patients with an inconclusive index bronchoscopy who were diagnosed
with lung cancer, the sensitivity of the classiﬁer was 89%, with 4 (11%) patients having a
false-negative classiﬁer result.
CONCLUSIONS: Invasive procedures after an inconclusive bronchoscopy occur frequently, and
most are performed in patients ultimately diagnosed with benign disease. Using the genomic
classiﬁer as an adjunct to bronchoscopy may reduce the frequency and associated morbidity
of these invasive procedures.
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Lesions that are suggestive of lung cancer on chest
imaging present a unique diagnostic challenge. Incidental
lung lesions are increasingly common given the rapid
rise in the use of chest computed tomography for a
variety of indications.1 Coupled with the recent evidence
from the National Lung Screening Trial supporting the
use of low-dose CT screening for lung cancer,2 there
will likely be a signiﬁcant increase in the identiﬁcation
of patients with suspicious lung lesions that require
diagnostic evaluation.
Bronchoscopy is often the initial diagnostic procedure
performed in patients with suspected lung cancer, and
can provide a deﬁnitive diagnosis and allows for
simultaneous staging.3 Despite advances such as
navigational and ultrathin bronchoscopy and peripheral
endobronchial ultrasound,4 the sensitivity of
bronchoscopy for smaller, peripherally located nodules
is limited.5 Given its limited sensitivity and low negative
predictive value, a bronchoscopy that does not provide
a deﬁnitive diagnosis of cancer frequently leads to
additional invasive testing, such as transthoracic needle
biopsy (TTNB) or surgical lung biopsy. In patients
with a low to intermediate probability of cancer and
an inconclusive bronchoscopy, the decision of whether
to pursue additional invasive testing or follow a plan
of watchful waiting can be a difﬁcult one. It requires
balancing the risks of invasive procedures in patients
who may have a benign lesion with the possibility of
a delayed lung cancer diagnosis.6
Recently a bronchial genomic classiﬁer was validated
in two prospective multicenter studies and was shown to
improve the sensitivity of bronchoscopy and better
identify patients who are at low probability (<10%)
of lung cancer after an inconclusive bronchoscopy.7,8
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epithelial cells collected from a mainstem bronchus
at the time of bronchoscopy.7,8 The classiﬁer does
not require direct sampling of the lung lesion, but
instead detects changes in lung cancer-associated gene
expression occurring in the airway “ﬁeld of injury.”9,10
In patients with a low or intermediate risk of cancer,
the classiﬁer achieved a sensitivity of 88% and speciﬁcity
of 52%. The sensitivity of the classiﬁer was similar
across different histologies and stages of lung cancer
and different lesion sizes. When bronchoscopy did not
result in a diagnosis of cancer, the observed rate
of lung cancer for patients with a negative classiﬁer
result was low (9%) among patients at intermediate
pretest probability of cancer (deﬁned as 10% to 60%),
and very low (0%) among patients with a low pretest
probability (deﬁned as < 10%).8
Although these previous studies establish clinical validity
of the genomic classiﬁer,7,8 the clinical utility of this
test has not been established. The performance of the
classiﬁer suggests that a negative score would support
a more conservative diagnostic approach in patients
with a low and intermediate pretest probability and
has the potential to reduce the use of invasive
procedures in patients who are likely to have benign
disease. The present study examines the rate of invasive
diagnostic procedures observed in the AEGIS trials7,8
with a low or intermediate pretest probability of
cancer as it is this population in which additional
diagnostic testing after an inconclusive bronchoscopy
is frequently performed and a biomarker with high
negative predictive value may result in greater utilization
of surveillance imaging. We also estimate the ability
of the classiﬁer to reduce the rate of invasive procedures
in patients ultimately diagnosed with benign disease.Methods
Study Population
The Airway Epithelial Gene Expression in the Diagnosis of Lung
Cancer (AEGIS) trials (AEGIS-1 and -2, NCT01309087 and
NCT00746759), were two prospective, multicenter (n ¼ 28 centers),observational studies that enrolled 939 current and former smokers
without a prior history of cancer who underwent bronchoscopy for
suspected lung cancer. The design of these studies has been
described in detail elsewhere.8 The study protocol was approved by
the institutional review board at each center, and all patients
provided written informed consent before enrollment.
At the time of bronchoscopy, two brushings of bronchial epithelial cells
from a normal-appearing area of a mainstem bronchus were collected
and proﬁled for gene expression by Gene 1.0 ST arrays (Affymetrix).
A 23-gene expression classiﬁer for detecting lung cancer (Percepta,
Veracyte Inc) was trained using samples from a cohort of
299 patients from AEGIS-1,7 then validated in samples from two
independent cohorts (AEGIS-1, n ¼ 298; and AEGIS-2, n ¼ 341).8
Physicians and patients were blinded to results of the classiﬁer.
Bronchoscopy was considered diagnostic if a lung cancer diagnosis
was established by cytopathology. All other patients were followed211
until a deﬁnitive diagnosis was established or 1 year after
bronchoscopy. Patients determined to be cancer-free had either a
speciﬁc benign diagnosis or radiographic stability or resolution by
12 months. Patients without a diagnosis of lung cancer, a speciﬁc
benign diagnosis, or stability or resolution at 12 months were
excluded from further analysis.
Prior to bronchoscopy, the treating physician assessed each patient’s
pretest probability of cancer with the use of a ﬁve-level scale
(< 10%, 10% to 39%, 40% to 60%, 61% to 85%, and > 85%), which
were then binned into three risk categories of low (< 10%),
intermediate (10% to 60%), and high (> 60%). Because our prior
studies found that the classiﬁer’s negative likelihood ratio of 0.06
would not reduce the posttest risk among the high pretest
probability group to less than 10%,8 the current analysis assesses the
classiﬁer’s impact on procedure utilization in the 222 patients (24%)
with a low or intermediate pretest probability (ie, < 60%) in which a
negative classiﬁer score would reduce the posttest risk of cancer to
less than 10% and potentially alter clinical decision making (ie,
deferring further invasive procedures and instead adopting
surveillance imaging).
Data Collection and Analysis of Classiﬁer
Baseline data collection included demographics, tobacco use, medical
history, and previous diagnostic tests. For patients in whom the
initial bronchoscopy did not yield a diagnosis of lung cancer, data
were collected on all subsequent diagnostic procedures within the
ﬁrst 12 months or until a cancer diagnosis was conﬁrmed.
Invasive procedures were categorized as repeat bronchoscopy, TTNB,
and surgical biopsy (open thoracotomy, video-assisted thoracoscopic
surgery, or mediastinoscopy). Other tests (eg, imaging, sputum
analysis, thoracentesis, bone scans, nuclear medicine scans,Figure 1 – Study exclusions used to identify the
population of patients with a low or intermediate
probability of cancer who had an inconclusive
bronchoscopy in AEGIS-1 and -2. A total of 222
patients in the AEGIS trials were found to have a
low or intermediate pretest probability of cancer.
Of those, 23 patients had a diagnosis of lung
cancer at bronchoscopy and the remaining 199
(90%) had an inconclusive bronchoscopy, in
which no malignancy was found. Longitudinal
diagnosis and procedure utilization data were
unavailable for 11 patients; the ﬁnal analytical
cohort of 188 patients consisted of 35 diagnosed
with lung cancer and 153 with benign diagnoses









212 Original Researchultrasound, and pulmonary function tests), as well as biopsies of
organs other than the lungs, were not considered in this analysis.
Statistical Analysis
Summary statistics are reported as medians and interquartile range for
continuous variables and as proportions for categorical variables.
Comparison of differences in baseline variables between low and
intermediate probability patients was calculated using the Mann-
Whitney U (Wilcoxon) test for continuous variables and Fisher exact
test for categorical variables. Subsequent invasive procedures after
the index bronchoscopy were summarized as counts and rates. These
were calculated overall, and stratiﬁed by pretest probability (low
vs intermediate). Procedures within the initial reporting period (0 to
3 months) vs the follow-up period (3 to 12 months) were counted
separately and together to examine the timing of procedure use.
Statistical analysis was performed using CRAN R software (version
3.2.1).
Because the performance of the classiﬁer (as measured by the area
under the curve) was not different between the training and two
validation sets (data not shown), they were combined for the
analysis of procedure utilization. Results of the classiﬁer were used to
estimate the number of patients in whom the decision to pursue
subsequent invasive procedures may have been inﬂuenced by the
test. The potential reduction in the rate of invasive procedure
utilization was calculated on the assumption that a negative classiﬁer
result would result in the treating physician deferring further
invasive procedures and instead adopting a watchful waiting
approach with surveillance imaging. Among patients who did not
have lung cancer identiﬁed on the index bronchoscopy, the number
and proportion of true-negative results (patients with benign disease
and a negative classiﬁer result) and false-negative results (patients
with lung cancer and a negative classiﬁer result) were reported.Results
Patient Population
There were 222 patients with a low or intermediate
pretest probability of cancer enrolled in AEGIS-1 and -2;
199 (90%) had an inconclusive index bronchoscopy
(Fig 1). Data on the subsequent use of additionalprocedures were available for 188 (94%) of these
patients; demographic data and details of the speciﬁc
bronchoscopic techniques used are shown in Table 1.
Patients with an intermediate probability were
signiﬁcantly older (P ¼ .001), had greater cumulative
tobacco exposure (P < .001), and were more likely to
have lesions greater than 3 cm in size (P ¼ .01), but theys with low or intermediate
bility of lung cancer




d 153 patients with
benign diagnoses
23 patients diagnosed with
malignancy at bronchoscopy
11 patients with no diagnostic
procedure data available
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(< 10%) (n ¼ 71)
Intermediate Probability
(10%-60%) (n ¼ 117) P Value
Sex
Female 68 (36) 26 (37) 42 (36) 1
Male 120 (64) 45 (63) 75 (64)
Age, y, median (IQR) 59.2 (50.4-69.0) 56.5 (46.3-65.5) 62.1 (52.7-70.6) .001
Race
Caucasian 149 (79) 61 (86) 88 (75) .23
African American 29 (15) 7 (10) 22 (19)
Other 8 (4) 3 (4) 5 (4)
Unknown 2 (1) 0 (0) 2 (2)
Smoking status
Current 63 (34) 21 (30) 42 (36) .43
Former 125 (66) 50 (70) 75 (64)
Pack-years, median (IQR) 25 (12-45) 15.5 (6-31) 34 (20-52) < .001
Mass size
< 2 cm 73 (39) 31 (44) 42 (36) .004
2 to 3 cm 23 (12) 5 (7) 18 (15)
$ 3 cm 40 (21) 8 (11) 32 (27)
Ill-deﬁned inﬁltrate 45 (24) 24 (34) 21 (18)
Unknown 7 (4) 3 (4) 4 (3)
Mass location
Central 61 (32) 29 (41) 32 (27) .07
Peripheral 75 (40) 21 (30) 54 (46)
Both 42 (22) 15 (21) 27 (23)
Unknown 10 (5) 6 (8) 4 (3)
Lung cancer histology 35 (19) 2 (3) 33 (28) 1
Small cell 2 (6) 0 (0) 2 (6)
Non-small cell 32 (91) 2 (100) 30 (91)
Adenocarcinoma 19 (54) 2 (100) 17 (52)
Squamous 9 (26) 0 (0) 9 (27)
Large cell 3 (9) 0 (0) 3 (9)
NSCLC, NOS 1 (3) 0 (0) 1 (3)
Unknown 1 (3) 0 (0) 1 (3)
Benign diagnoses 153 (81) 69 (97) 84 (72) .10
Infection 32 (21) 10 (14) 22 (26)
Sarcoidosis 36 (24) 22 (32) 14 (17)
Resolution or stability 43 (28) 18 (26) 25 (30)
Other 42 (27) 19 (28) 23 (27)
Bronchoscopy techniquea 188 (100) 71 (100) 117 (100) .
Standard 81 (43) 30 (42) 51 (44)
Standard þ EBUS-TBNA 75 (40) 29 (41) 46 (39)
Standard þ EMN 2 (1) 1 (1) 1 (1)
Standard þ EBUS-TBNA þ EMN 7 (4) 0 (0) 7 (6)
Data unavailable 23 (12) 11 (15) 12 (10)
Data reported as No. (%) unless otherwise indicated. EBUS ¼ endobronchial ultrasound; EMN ¼ electromagnetic navigation; IQR ¼ interquartile range;
NOS ¼ not otherwise speciﬁed; NSCLC ¼ non-small cell lung cancer; TBNA ¼ transbronchial needle aspiration.
aDeﬁned as sampling that included use of cytological brush, endobronchial biopsy, transbronchial biopsy, and/or bronchoalveolar lavage.
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were similar in terms of race and sex distribution.
Overall, lung cancer was diagnosed in 35 patients (19%);
the remaining 153 (81%) were ultimately diagnosed
with benign disease. In patients with an inconclusive
bronchoscopy, the lung cancer prevalence was 3% and
28% in patients with a low and intermediate pretest
probability, respectively.
Diagnostic Procedure Utilization
In the 188 patients with an inconclusive index
bronchoscopy, subsequent invasive biopsy procedures
were performed in 77 (41%) (Table 2). A total of
99 procedures were performed in these 77 patients
and included 18 procedures in 15 patients with low
probability and 81 procedures in 62 patients with
intermediate probability. The type and rate of
subsequent invasive procedures performed among
these 77 patients included surgical lung biopsy in
40 (52%) patients, TTNB in 20 (26%) patients, and
repeat bronchoscopy in 39 (51%) patients. Physicians
were more likely to pursue additional procedures in
patients with an intermediate probability compared
with those with low probability (53% vs 21%; P < .001)
(Table 2).
Forty-two (55%) of the 77 patients in the combined low
and intermediate probability categories who underwent
additional invasive testing were ultimately diagnosed
with benign disease. Among patients with intermediate
probability who underwent a subsequent procedure,
29 (47%) of 62 patients were diagnosed with benign
disease, compared with 13 (87%) of 15 patients with
low probability who were found to have benign
disease (Fig 2A). Among the 42 patients with benign
disease, a total of 52 procedures were performed, with
16 procedures performed in 13 patients with low
probability and 36 procedures performed in 29 patients
with intermediate probability (Fig 2B).
Among the 77 patients who underwent subsequent
invasive testing, 40 (52%) had a surgical lung biopsy, ofTABLE 2 ] Invasive Procedures After an Inconclusive Bron
Variable All Low Pro
Total No. of patients 188
Patients with any invasive procedure 77 (41)
Repeat bronchoscopy 39 (21)
Transthoracic needle aspiration 20 (11)
Surgery 40 (21)
Total procedures 99
Data are reported as No. (% of total).
214 Original Researchwhich half were performed in patients with benign
disease (20 of 40 patients); this included 86% (6 of 7) in
patients with low probability and 42% (14 of 33) in
patients with intermediate probability, respectively.
To examine the likelihood of a delayed lung cancer
diagnosis, we calculated the timing of additional invasive
procedures in the 35 patients diagnosed with lung cancer
after an inconclusive bronchoscopy; 27 (80%) had a lung
cancer diagnosis established within 3 months of the
index bronchoscopy, whereas 8 (20%) had a delay in
their diagnosis of between 3 and 12 months.
Potential Impact of the Classiﬁer on Invasive
Procedure Utilization
The potential for the bronchial genomic classiﬁer to
reduce the number of invasive procedures in patients
with an inconclusive bronchoscopy was assessed by
examining the rate of a negative classiﬁer result among
patients who underwent subsequent invasive
procedures. This analysis assumes that a negative
classiﬁer score would result in a decision to use
surveillance imaging instead of proceeding to an
additional invasive procedure. Among the 153 total
patients with benign disease (including 84 patients
with intermediate and 69 patients with low pretest
probability), 83 (54%) had a negative classiﬁer result,
yielding a reduction in the posttest probability of cancer
(Fig 3A). Forty-one (49%) patients with intermediate
probability were determined to have a low posttest
probability on the basis of a negative classiﬁer result,
with the balance of patients remaining at intermediate
posttest probability. Forty-two (61%) patients with low
pretest probability were determined to have a very low
posttest probability on the basis of a negative classiﬁer
result, whereas the remaining 27 (39%) remained at low
posttest probability.
Of the 153 patients with low and intermediate pretest
probability who had benign disease, 42 (27%) underwent
a total of 52 subsequent invasive procedures. Thechoscopy
bability (< 10%) Intermediate Probability (10%-60%) P Value
71 117
15 (21) 62 (53) .004
10 (14) 29 (25) .198
1 (1) 19 (16) .002
7 (10) 33 (28) .016
18 81
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Figure 3 – A, Potential clinical utility of the bronchial genomic classiﬁer
is shown for total patients ultimately diagnosed with benign disease
(n ¼ 153), consisting of 84 (55%) with intermediate pretest probability
of lung cancer and 69 (45%) with low probability. Forty-one (49%)
patients with intermediate pretest probability had a negative classiﬁer
score and were correctly predicted to have a low posttest probability.
Forty-two (61%) patients with low pretest probability had a negative
score and were correctly predicted to have a very low posttest probability.
B, Potential clinical utility of the bronchial genomic classiﬁer is shown
for patients diagnosed with benign disease who underwent invasive
procedures after an inconclusive bronchoscopy. Invasive procedures
could have been avoided in 21 (50%) of 42 patients, including 12 (41%)
of 29 patients with intermediate probability and 9 (69%) of 13 patients
with low probability. Four (31%) of 13 patients with a low pretest
probability who went on to have additional procedures had a positive
classiﬁer result, which would likely not have resulted in a change in
the diagnostic approach chosen for these patients.
Invasive procedure for benign disease























Figure 2 – A, Patient-level analysis of subsequent invasive procedures
after inconclusive bronchoscopy is shown. The number of patients
stratiﬁed by physician-assigned pretest probability of lung cancer
categories—low (< 10%) or intermediate (10%-60%)—who had
invasive procedures (shaded) was compared with those who did not
have invasive procedures (unshaded) during the study period. Among
patients who had invasive procedures, the number of patients who
were diagnosed with benign disease is shaded black. B, Procedure-level
analysis of subsequent invasive procedures after inconclusive bronchos-
copy is shown. The absolute number of procedures performed in patients
in low and intermediate pretest probability groups are presented;
procedures performed on patients with benign disease are shaded black.classiﬁer was negative (ie, true negatives) in 21 (50%)
patients, leading to the possible avoidance of 24
procedures (including 12 bronchoscopies, 3 TTNA,
and 9 surgeries). This represents a 46% (24 of 52)
reduction in all invasive procedures performed in
patients with benign disease. Of the 21 patients with
benign disease who were classiﬁer negative, 9 (43%)
were patients with low pretest probability, and 12 (57%)
were patients with intermediate pretest probability
(Fig 3B).
Among 35 patients with an inconclusive index
bronchoscopy who were diagnosed with lung cancer,
there were 4 patients with a negative classiﬁer result
(false-negative rate of 11%) (Fig 4). This occurred in
4 patients with an intermediate pretest probability of
cancer prior to bronchoscopy in whom a negative
classiﬁer result yielded a low posttest probability.
Discussion
In this study, we examined the rate of invasive
diagnostic procedures among current and former
smokers with low and intermediate pretest probability
of cancer after an inconclusive bronchoscopy. We foundjournal.publications.chestnet.orgthat there is a relatively high frequency of invasive
diagnostic procedures in this clinical setting (41%overall),
with a majority of those procedures occurring in patients
ultimately diagnosed with benign disease. Our estimates
suggest that a signiﬁcant proportion of invasive
procedures could be avoided after an inconclusive
bronchoscopy with the use of the genomic classiﬁer.
Subsequent invasive procedures after an inconclusive
bronchoscopy have the potential for substantial
morbidity from procedural complications. In this
study 50% of surgical lung biopsies were performed
in patients with benign disease. This rate is consistent
with the rate of surgical biopsies resulting in a
diagnosis of benign disease seen in lung cancer screening
studies and in a population-based study of lung
nodule management.2,11-14 Surgical lung biopsy has a
moderate complication rate and a 30-day mortality of
approximately 1%.15,16 TTNB is also associated with
substantial complications, including a 15% rate of














Figure 4 – Pretest and posttest probability of cancer as assessed by
physicians and the genomic classiﬁer is shown for the 35 patients
diagnosed with lung cancer during the study period. Overall, 31 (89%)
patients with lung cancer had a positive classiﬁer score, and 4 (11%) had
a negative classiﬁer score (ie, false negatives). Of the 33 patients with an
intermediate pretest probability, 29 (88%) had a positive classiﬁer score,
and 4 (12%) had a negative classiﬁer score. Of the 2 patients with a low
pretest probability, 100% had a positive score.requiring chest tube drainage.17-19 The classiﬁer will
likely result in a reduction in invasive procedure
utilization in patients with low and intermediate pretest
probability lesions, the majority of whom have benign
disease. Fifty-four percent of patients with benign
disease and an inconclusive bronchoscopy had a
negative classiﬁer result, enabling a lower postclassiﬁer
probability of cancer, which could facilitate the decision
by physicians to recommend watchful waiting rather
than proceed with another invasive procedure. Of the
patients with benign disease who subsequently
underwent additional procedures, 50% had a negative
classiﬁer result. The primary clinical value of the
bronchial genomic classiﬁer is conferred on patients
with an intermediate probability and an inconclusive
bronchoscopy in whom a negative classiﬁer results in
a low posttest likelihood of lung cancer. The classiﬁer
may also be useful in patients with a low pretest
probability as the majority (87%) who went on to an
invasive procedure had a negative classiﬁer result and
were ultimately diagnosed with benign disease.
In the current study, 4 (11%) of 35 patients with lung
cancer had a negative classiﬁer result (false negatives)
and may have experienced a delayed diagnosis if they
were followed with surveillance imaging as a result of
the classiﬁer. However, we found that in the absence of
the classiﬁer, 20% (7 of 35) of patients with lung cancer
and an inconclusive bronchoscopy were not diagnosed216 Original Researchwithin 3 months after their initial procedure because of
a decision to pursue surveillance imaging prior to the
decision to pursue additional procedures. The low rate
of false-negative results observed with the classiﬁer may
result in a modest increase in the number of patients
with lung cancer who undergo surveillance prior to
additional invasive evaluation. If patients with a negative
classiﬁer are evaluated with serial imaging (ie, repeat
scan at 3 months) there should not be a lengthy delay
in identifying lesions that are growing that should
proceed to another biopsy.
Although the AEGIS trials provided us with a unique
opportunity to estimate the clinical utility of the
bronchial genomic classiﬁer, there are a number of
important limitations to our study. In our current
analysis we estimated the ability of the classiﬁer to
decrease subsequent invasive procedure utilization.
This approach rests on the underlying assumption
that a negative classiﬁer result would have been
sufﬁcient to warrant a more conservative diagnostic
evaluation in patients who would have otherwise been
sent for an invasive procedure. Our study was not
designed to assess the factors associated with physicians’
decisions to pursue additional invasive procedures.
In addition, as physicians were blinded to results of
the classiﬁer we are unable to directly evaluate the
actual impact of that classiﬁer on their decision making.
In some patients with a negative classiﬁer result,
physicians may still choose to proceed with further
invasive testing. We also did not estimate the effect
that patient preferences may have on subsequent
invasive procedure utilization after an inconclusive
bronchoscopy. Importantly, we were unable to evaluate
whether some of the invasive procedures in patients
with benign disease resulted in a diagnosis that altered
clinical management of that patient, providing clinically
useful results to the physician.
Given that these observational studies did not mandate
that subsequent evaluation after bronchoscopy occur
at the study center, there may have been additional
invasive procedures performed that are not accounted
for in our data. The studies were limited to 12 months
of clinical follow-up after the index bronchoscopy.
We do not believe that we missed a signiﬁcant number
of lung cancers that would have been found with an
additional year of follow-up. The high sensitivity of
CT to detect nodule growth makes it unlikely that
solid nodules that are stable for 12 months will grow
subsequently. This is supported by lung cancer screening
studies that showed only 1 of 1000 nodules that were[ 1 5 0 # 1 CHE S T J U L Y 2 0 1 6 ]
stable in the ﬁrst year were determined to be malignant
in the second year of follow-up.13 Finally, we used
data from all patients enrolled in both trials given
the similar accuracy estimates observed in the training
and test sets. As our goal was to estimate downstream
procedure use after an index bronchoscopy, the similar
area under the curve estimates allowed for this approach
to increase statistical power.
There are a number of strengths to our study that
contribute to the potential impact of our ﬁndings.
First, we leveraged two large multicenter studies that
enabled us to include geographically diverse academic
and community practices in our estimate of invasive
procedure use. Second, our data were collected in a
clinical setting identical to that in which the classiﬁer
would be used (before diagnosis), allowing us to better
estimate the potential clinical utility of the test. Third,
we limited these studies to patients with low and
intermediate pretest probability in whom physicians
are most uncertain about the likelihood of cancer and
in whom the classiﬁer holds the greatest ability tojournal.publications.chestnet.orgalter clinical decision making. Finally, the probability
of cancer was based on a physician’s subjective
assessment (as opposed to risk prediction models),
which both mirrors clinical practice and was shown
to reﬂect cancer prevalence rates in the AEGIS trials.8
In summary, there is a high frequency of invasive
procedures performed in patients with a low or
intermediate pretest probability of lung cancer after
an inconclusive bronchoscopy, and a majority of
these procedures are performed in patients ultimately
diagnosed with benign disease. This analysis suggests
that using the bronchial genomic classiﬁer during
bronchoscopy may reduce invasive procedures in this
population. Future studies should attempt to conﬁrm
reductions in invasive procedures that result from the
ﬁnding of a negative genomic classiﬁer that prompts
a physician to pursue serial imaging surveillance after
an inconclusive bronchoscopy, as well as examine the
impact of the classiﬁer on cancer end points such
as stage at diagnosis and the impact on costs and
patient-reported outcomes.Acknowledgments
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